RxDoctor Payments Data

Jeffrey Farmer, MD

Ophthalmology · Murfreesboro, TNNPI 1316478811

Payments from drug & device makers

$2,416in general payments, 2019–2025

Across 106 payments — averaging $22.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$754
  • AbbVie$312
  • Bausch & Lomb Americas Inc.$271
  • Novartis$180
  • Biotissue Holdings Inc.$160
  • Oyster Point Pharma, Inc.$148
  • plus $591 from 9 others

What the payments were for

  • Food & beverage$2,416100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,416 in reported general payments places this provider in the 55th percentile of 323 ophthalmology providers in Tennessee.

See all ophthalmology providers in Tennessee

Medicare billing

Part B allowed, 2024
$235,840
Medicare patients
843
Services billed
1,681

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast53$66,237
LumiganBimatoprost75$26,349
RestasisCyclosporine30$22,278
MieboPerfluorohexyloctane/Pf16$14,342
Prednisolone Acetate262$8,813
Alphagan PBrimonidine Tartrate14$4,898
Latanoprost265$3,761
Ketorolac Tromethamine186$3,701
MoxifloxacinMoxifloxacin Hcl134$3,131
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha121$1,624
Travoprost17$1,495
Timolol Maleate113$1,079
Bimatoprost21$928
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat59$899
Brimonidine Tartrate100$867

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Miebo$271$80,57969 claims
AbbVieLumigan, Restasis, Alphagan P$312$53,525119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 323 ophthalmology providers in Tennessee.

Other ophthalmology in Murfreesboro

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →